Effects of kanglaite capsules combined with transcatheter arterial chemoembolization (TACE) on patients with mid or late-stage primary hepatocellular carcinoma (HCC)

Abstract

To observe the clinical effects of kanglaite (KLT) capsules combined with transcatheter arterial chemoembolization (TACE) in treating patients with mid or late-stage primary hepatocellular carcinoma (HCC). Sixty-five cases were randomly divided into 2 groups, 32 patients in combination group received the treatment of KLT capsules + TACE and 33 patients in control group were treated with TACE alone. The objective response rate (RR), serum alpha fetoprotein (AFP), peripheral blood T lymphocyte subgroups (T-LS), quality of life (QOL), time to progression (TTP) and adverse reaction were observed and compared between 2 groups. The objective response rate and serum alpha fetoprotein levels had no significant difference between the two groups (P > 0.05). Combination group was superior to control group in quality of life (QOL), time to progression (TTP), peripheral blood T lymphocyte subgroups (CD3+, CD4+, CD4+∖CD8 ratio) and liver adverse reactions, with significant differences (P < 0.05). KLT capsules combined with TACE is an effective method to treat primary hepatocellular carcinoma (HCC) patients who have lost the opportunity of surgical therapy.